Calidi Biotherapeutics Inc. (CLDI), a clinical-stage biotechnology company, released on Monday new data on the approach of simultaneous T-cell activation and expression of T-cell engagers in the tumor microenvironment at the 2026 annual meeting of the American Association of Cancer Research (AACR).
Calidi has been developing the RedTail virotherapy platform, consisting of viruses that target tumors while modifying the tumor microenvironment (TME), enabling a high-level expression of therapeutic genetic payloads directly at the tumor sites.
Data released by the company indicates that RedTail viruses express T-cell engagers and target solid tumor cells by T-cell activation. Historically, while T-cell engagers showed efficacy in haemotological malignancies, they were not effective against solid tumors as the TME inhibited immune cell infiltration. With the approach of remodelling the TME and simultaneously driving T-cell activation alongside expression of a T-cell engager, RedTail can overcome these limitations.
CLD-401 is the company's lead drug from the RedTail platform and expresses high levels of interleukin 15 superagonist (IL-15 SA) in the TME. An investigational new drug (IND) application is expected to be filed by the end of this year.
CLDI closed Monday at $0.25, down 9.02%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.